Clinical Trial Update: Efficacy of NVA237 (50 μg o.d) Using Tiotropium (5μg μg o.d) as Active Control in COPD Patients. [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating NVA237 (umeclidinium) at 50 μg once daily with tiotropium as an active control in COPD patients was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• NVA237
• tiotropium (tiotropium)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 3 | Status: WITHDRAWN